drugset / Trial / NCT00002637
Biological Therapy in Treating Patients With Prostate Cancer
Treatment
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy using interleukin-2 and interferon gamma in treating patients with advanced prostate cancer.
Timeline
- Start
- 1995-01
- Primary completion
- 2001-02
- Completion
- 2001-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LNCaP cells | Unknown | — | — |
| Subject | aldesleukin | Protein / enzyme biologic | — | — |
| Subject | interferon gamma | Protein / enzyme biologic | — | — |